Fused 1,4-oxazepines as BET protein degraders

US11466028B2 · kind B2 · utility

Assignee

• THE REGENTS OF THE UNIVERSITY OF MICHIGAN · US

Inventors

• Shaomeng Wang · Saline, US
• Yang Hu · Brookline, US
• Chong Qin · Ann Arbor, US
• Fuming Xu · Ypsilanti, US
• Jiantao Hu · Ann Arbor, US
• Bing Zhou · Ann Arbor, US
• Zhuo Chen · Beijing, CN
• Ester Fernandez-Salas · San Mateo, US
• Longchuan Bai · Ann Arbor, US
• Donna McEachern · Ann Arbor, US

Key dates

• Filing date: Sep 13, 2017
• Grant date: Oct 11, 2022
• Expiry date: May 26, 2039

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P37/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure provides compounds represented by Formula I and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1, R2a, R2b, R3a, R3b, R4, Ar, L, X, Y, and B are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to degradation of BET bromodomains such as cancer.